ACGME Program Requirements for Graduate Medical Education
in Hematology and Medical Oncology
Summary and Impact of Focused Requirement Revisions

Requirement:  Multiple

Requirement Revision (significant change only):
“or AOBIM” added to any program requirement that referred to the certification qualification for
the program director, the minimum number of subspecialty-certified core faculty, and the
availability of faculty members from other internal medicine subspecialties.

1. Describe the Review Committee’s rationale for this revision:
   These program requirements are revised to make it explicit that AOBIM is an
   acceptable certification to meet the qualification requirements for program
director, subspecialty physician core faculty member, and the faculty members
from other internal medicine subspecialty programs who must be available for
the education of fellows.

2. How will the proposed requirement or revision improve resident/fellow education, patient
   safety, and/or patient care quality?
   This will not affect resident/fellow education, patient safety, and/or patient care
   quality.

3. How will the proposed requirement or revision impact continuity of patient care?
   This will not affect continuity of patient care.

4. Will the proposed requirement or revision necessitate additional institutional resources
   (e.g., facilities, organization of other services, addition of faculty members, financial
   support; volume and variety of patients), if so, how?
   This will not necessitate additional institutional resources.

5. How will the proposed revision impact other accredited programs?
   This will not affect other accredited programs.
Requirement: II.B.4.c)-e)

Requirement Revision (significant change only):

In addition to the program director, there must be at least three core faculty members certified in hematology or medical oncology by the ABIM or the AOBIM. (Core)

Among the program director and the core faculty members, at least two individuals must be certified in hematology by the ABIM or AOBIM, and at least two individuals must be certified in medical oncology by the ABIM or AOBIM. (Core)

For programs approved for more than six fellows, there must be at least one core faculty member certified in hematology or medical oncology by the ABIM or the AOBIM. (Core)

1. Describe the Review Committee's rationale for this revision:
   The Committee is supplementing the “Core Faculty” section of the Common Program Requirements with its long-standing requirement that there be a minimum number of faculty members who are certified in the subspecialty. At the same time, it is reducing that number from six to three to be consistent with other internal medicine subspecialties.

2. How will the proposed requirement or revision improve resident/fellow education, patient safety, and/or patient care quality?
   This will not affect resident/fellow education, patient safety, and/or patient care quality.

3. How will the proposed requirement or revision impact continuity of patient care?
   This will not affect continuity of patient care.

4. Will the proposed requirement or revision necessitate additional institutional resources (e.g., facilities, organization of other services, addition of faculty members, financial support; volume and variety of patients), if so, how?
   This will not necessitate additional institutional resources.

5. How will the proposed revision impact other accredited programs?
   This will not affect other accredited programs.
Requirements: Multiple

Requirement Revision (significant change only):

Section IV.B.1.b) (ACGME Competencies > Patient Care and Procedural Skills
Section IV.B.1.c) (ACGME Competencies > Medical Knowledge)

Many of the specialty-specific competencies have been updated.

1. Describe the Review Committee’s rationale for this revision:

   These revisions represent the evolution of the subspecialty and the current standard of practice. They are proposed in response to feedback from the community, particularly the American Board of Internal Medicine Hematology Board, the American Board of Internal Medicine Medical Oncology Board, the American Society of Hematology, and the American Society of Clinical Oncology.

2. How will the proposed requirement or revision improve resident/fellow education, patient safety, and/or patient care quality?

   This will not affect resident/fellow education, patient safety, and/or patient care quality.

3. How will the proposed requirement or revision impact continuity of patient care?

   This will not affect continuity of patient care.

4. Will the proposed requirement or revision necessitate additional institutional resources (e.g., facilities, organization of other services, addition of faculty members, financial support; volume and variety of patients), if so, how?

   This will not necessitate additional institutional resources.

5. How will the proposed revision impact other accredited programs?

   This will not affect other accredited programs.